Loomis Sayles & CO L P Spring Works Therapeutics, Inc. Transaction History

Loomis Sayles & CO L P

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$18.36 - $60.07 $9.77 Million - $32 Million	-532,164 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$48.97 - $65.46 $497,143 - $664,549	-10,152 Reduced 1.87%	532,164 $30 Million
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $779,459 - $1.11 Million	-14,624 Reduced 2.63%	542,316 $33.6 Million
Q3 2021 Nov 12, 2021	SELL	$62.66 - $88.26 $541,257 - $762,389	-8,638 Reduced 1.53%	556,940 $35.3 Million
Q2 2021 Aug 13, 2021	SELL	$67.45 - $85.63 $772,572 - $980,806	-11,454 Reduced 1.98%	565,578 $46.6 Million

Q1 2021 May 17, 2021	SELL	$65.1 - $93.59 $130,981 - $188,303	-2,012 Reduced 0.35%	577,032 $42.5 Million
Q4 2020 Feb 12, 2021	SELL	$48.36 - $77.92 $156,831 - $252,694	-3,243 Reduced 0.56%	579,044 $42 Million
Q3 2020 Nov 12, 2020	BUY	$36.14 - $51.99 $5.55 Million - $7.99 Million	153,643 Added 35.84%	582,287 $27.8 Million
Q2 2020 Aug 14, 2020	BUY	$22.98 - $48.57 $9.85 Million - $20.8 Million	428,644 New	428,644 $18 Million

234

67.7M

546K

29.4K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.35B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

Stay updated on Loomis Sayles & CO L P with notifications on news.